Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML

Tyrosine kinase inhibitor (TKI) combination is expected to increase in the era of precision medicine. TKI combination may be required to treat double primary cancers, each having a targetable gene, or to treat a single malignancy with multiple targetable genes. Here, we demonstrate the first report...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Kousuke, Kage, Hidenori, Nagoshi, Saki, Toyama, Kazuhiro, Ohno, Yoshiyuki, Shinozaki-Ushiku, Aya, Nakazaki, Kumi, Suzuki, Hiroshi, Kurokawa, Mineo, Nagase, Takahide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106872/
https://www.ncbi.nlm.nih.gov/pubmed/32257476
http://dx.doi.org/10.1155/2020/4201727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106872/
https://www.ncbi.nlm.nih.gov/pubmed/32257476
http://dx.doi.org/10.1155/2020/4201727

Ejemplares similares